title: [Correlation of TOP2A gene expression and survival of breast cancer patients].
abstract: OBJECTIVE
  The aim of this study was to assess the TOP2A RNA expression and the relationship of TOP2A protein expression with metastasis-free interval in breast cancer patients.
  
  
  METHODS
  TOP2A expression was analyzed prior to surgery in 86 patients. The level of TOP2A gene amplification was analyzed by fluorescence in situ hybridization (FISH), its RNA expression level with RT-PCR, and their correlation with TOP2A protein expression was assessed by immunohistochemistry (IHC). The correlation between RNA expression level and metastasis-free interval in breast cancer patients was also analyzed.
  
  
  RESULTS
  Aberrations (amplification or deletion) of TOP2A copy number was observed in 25.6% (22/86) of the cases. TOP2A protein expression was detected in 66.3% (57/86) of the samples. There was a significant correlation between the TOP2A RNA expression and protein expression (P < 0.001). TOP2A gene expression was significantly associated with the metastasis-free interval in the breast cancer patients (P = 0.001). There was no significant correlation between TOP2A gene amplification and TOP2A protein expression (P = 0.211).
  
  
  CONCLUSIONS
  TOP2A RNA level is an objective and reliable prognostic indicator in breast cancer.
authors.affiliation: Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Meng
authors.forename: Wen-cai
authors.initials: WC
authors.lastname: Li
authors.forename: Liu-xing
authors.initials: LX
authors.lastname: Wang
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Li
authors.forename: Lan
authors.initials: L
authors.lastname: Zhang
authors.forename: Qing-xia
authors.initials: QX
authors.lastname: Fan
authors.forename: Rui-lin
authors.initials: RL
authors.lastname: Wang
authors.forename: Tai-ying
authors.initials: TY
authors.lastname: Lu
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005784:Gene Amplification; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000075223:Poly-ADP-Ribose Binding Proteins; D012313:RNA / Q000378:metabolism; D012074:Remission Induction
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D012313:RNA; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human